Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication

Andrew V Stachulski, Chandrakala Pidathala, Eleanor C Row, Raman Sharma, Neil G Berry, Alexandre S Lawrenson, Shelley L Moores, Mazhar Iqbal, Joanne Bentley, Sarah A Allman, Geoffrey Edwards, Alison Helm, Jennifer Hellier, Brent E Korba, J Edward Semple, Jean-Francois Rossignol

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


We report the activities of a number of thiazolides [2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis C virus (HCV) genotypes IA and IB, using replicon assays. The structure-activity relationships (SARs) of thiazolides against HCV are less predictable than against hepatitis B virus (HBV), though an electron-withdrawing group at C(5') generally correlates with potency. Among the related salicyloylanilides, the m-fluorophenyl analogue was most promising; niclosamide and close analogues suffered from very low solubility and bioavailability. Nitazoxanide (NTZ) 1 has performed well in clinical trials against HCV. We show here that the 5'-Cl analogue 4 has closely comparable in vitro activity and a good cell safety index. By use of support vector analysis, a quantitative structure-activity relationship (QSAR) model was obtained, showing good predictive models for cell safety. We conclude by updating the mode of action of the thiazolides and explain the candidate selection that has led to compound 4 entering preclinical development.
Original languageEnglish
Pages (from-to)8670-80
Number of pages11
JournalJournal of Medicinal Chemistry
Issue number24
Publication statusPublished - 22 Dec 2011


  • Amides
  • Antiviral Agents
  • Cell Line
  • Hepacivirus
  • Humans
  • Quantitative Structure-Activity Relationship
  • Thiazoles
  • Virus Replication


Dive into the research topics of 'Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication'. Together they form a unique fingerprint.

Cite this